Inflammatory Bowel Disease: Calming a Gut That Attacks Itself
Unlike IBS, where the gut looks normal, inflammatory bowel disease is real, visible inflammation — the immune system attacking the bowel wall, causing ulcers, bleeding and pain. Treatment follows a clear ladder of increasingly powerful immune-calming drugs, and the strategy has two distinct jobs: put out the fire, then keep it from reigniting.
Inflammatory bowel disease (IBD) is quite different from the irritable bowel syndrome of the last section. IBS is a functional problem — the gut is oversensitive but looks normal. IBD is structural, real inflammation: the immune system mistakenly attacks the lining of the bowel, causing ulcers, bleeding, diarrhoea (often bloody), pain and weight loss, with visible damage on examination. There are two main forms — ulcerative colitis (affecting the colon) and Crohn's disease (which can affect any part of the gut) — and while they differ, their drug treatment shares the same core logic. Because the problem is an over-active immune attack, the treatment is a series of drugs that calm the immune system, arranged as a ladder of increasing strength — and used with a two-part strategy that's worth grasping first.
Induce, then maintain — the two-part strategy
First put out the flare; then prevent the next one. IBD comes in flares — periods where the inflammation flares up badly — separated by quieter times. So treatment has two distinct goals, and different drugs suit each. First, inducing remission: when the disease is actively flaring, you need to put the fire out fast with a powerful anti-inflammatory. This is the classic job of corticosteroids (from the endocrine chapter) — they rapidly suppress the inflammation and settle a flare. But — and this is the key point — steroids are for the flare only, NOT for long-term use, because of all their serious side effects you already know (diabetes, osteoporosis, and the rest). So once the fire is out, you switch to the second goal: maintaining remission — keeping the disease quiet long-term with safer drugs that don't carry the steroid burden. Getting this distinction right is central to IBD care: use steroids to induce remission quickly, then get the patient OFF steroids onto a maintenance drug to keep them well. Steroids are a fire extinguisher, not a way of life.
The ladder of drugs
The drugs form a ladder of increasing potency. At the bottom sit the aminosalicylates (5-ASA drugs, like mesalazine) — mild anti-inflammatories that act locally on the bowel lining. They're the mainstay for mild ulcerative colitis, used both to settle mild flares and, importantly, as safe long-term maintenance. Next up are the corticosteroids, used as above to induce remission in a flare but not for maintenance. When aminosalicylates aren't enough to keep the disease quiet, or the patient keeps needing steroids, you climb to the immunosuppressants — drugs that dampen the immune system more broadly, used for long-term maintenance to keep patients off steroids. The classic ones are azathioprine (and mercaptopurine) and methotrexate. These are effective but require monitoring, because suppressing the immune system brings risks: increased infection, and effects on the blood counts and liver that need regular blood tests. A specific, memorable caution links back to earlier chapters: azathioprine is dangerously potentiated by allopurinol (the gout drug), because allopurinol blocks the enzyme that breaks azathioprine down — so the combination can cause severe toxicity. Above this ladder sit the biologics, the modern game-changers for moderate-to-severe disease, which get their own article next. The shape to remember: aminosalicylates → steroids (flares only) → immunosuppressants → biologics, always with the induce-then-maintain strategy in mind.
- IBD (ulcerative colitis, Crohn's) = real immune-driven bowel inflammation — unlike functional IBS.
- Two-part strategy: INDUCE remission (put out the flare) then MAINTAIN remission (keep it quiet).
- Steroids induce remission fast but are for flares ONLY — never long-term maintenance.
- Ladder: aminosalicylates (mesalazine) → steroids (flares) → immunosuppressants (azathioprine, methotrexate) → biologics.
- Immunosuppressants need monitoring (infection, blood counts, liver); azathioprine + allopurinol = dangerous toxicity.
The single most important principle in IBD treatment is that steroids put out fires but must never be left burning. A corticosteroid is superb at rapidly quenching a flare — but everything you learned in the endocrine chapter about its long-term harms (diabetes, osteoporosis, adrenal suppression, infection risk) means it's a terrible maintenance drug. So the whole art of IBD care is to use steroids briefly to induce remission, then transition the patient onto something safer for the long haul — an aminosalicylate, an immunosuppressant, or a biologic — to keep the disease quiet without the steroid toll. A patient who keeps needing repeated or continuous steroids to stay well is a red flag that their maintenance treatment needs stepping up. 'Induce with steroids, maintain with something else' is the sentence that captures the whole strategy.
- Keeping a patient on steroids long-term for IBD — steroids are for flares, not maintenance.
- Combining azathioprine with allopurinol without adjustment — severe toxicity.
- Not monitoring immunosuppressants (blood counts, liver, infection risk).
- Confusing IBD with IBS — IBD is real inflammation needing immune-calming drugs.
What is the role of corticosteroids in inflammatory bowel disease?
- IBD = real immune-driven bowel inflammation (ulcerative colitis, Crohn's) — not functional like IBS.
- Strategy: induce remission (steroids, briefly) then maintain remission (safer drugs).
- Ladder: aminosalicylates → steroids (flares) → immunosuppressants → biologics.
- Monitor immunosuppressants; azathioprine + allopurinol is a dangerous combination.
- Katzung BG. Basic & Clinical Pharmacology — Drugs Used in Inflammatory Bowel Disease.
- Brunton LL, et al. Goodman & Gilman's The Pharmacological Basis of Therapeutics — Treatment of IBD.
- ECCO / ACG — Guidelines on ulcerative colitis and Crohn's disease.
- Whalen K. Lippincott Illustrated Reviews: Pharmacology — IBD therapy.
